Spironolactone is associated with reduced mitotane levels in adrenocortical carcinoma patients

Haberbosch, Linus; Maurer, Lukas; Sandforth, Arvid; Wernicke, Charlotte; Spranger, Joachim; Mai, Knut; von Schwartzenberg, Reiner Jumpertz

dc.contributor.author	Sandforth, Arvid
dc.contributor.author	Jumpertz-von Schwartzenberg, Reiner
dc.date.accessioned	2023-01-17T06:57:55Z
dc.date.available	2023-01-17T06:57:55Z
dc.date.issued	2022
dc.identifier.issn	1351-0088
dc.identifier.uri	http://hdl.handle.net/10900/135430
dc.language.iso	en	de_DE
dc.publisher	Bioscientifica Ltd	de_DE
dc.relation.uri	http://dx.doi.org/10.1530/ERC-21-0202	de_DE
dc.subject.ddc	610	de_DE
dc.title	Spironolactone is associated with reduced mitotane levels in adrenocortical carcinoma patients	de_DE
dc.type	Article	de_DE
utue.quellen.id	20220728000000_01764
utue.publikation.seiten	121-128	de_DE
utue.personen.roh	Haberbosch, Linus
utue.personen.roh	Maurer, Lukas
utue.personen.roh	Sandforth, Arvid
utue.personen.roh	Wernicke, Charlotte
utue.personen.roh	Spranger, Joachim
utue.personen.roh	Mai, Knut
utue.personen.roh	von Schwartzenberg, Reiner Jumpertz
dcterms.isPartOf.ZSTitelID	Endocrine - Related Cancer	de_DE
dcterms.isPartOf.ZS-Issue	3	de_DE
dcterms.isPartOf.ZS-Volume	29	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE